On May 15, Medaverse (Pharma Universe) released its 2022 Top 50 Global Pharmaceutical Companies list, which ranks pharmaceutical companies based on their sales revenue of prescription drug in 2021, with six Chinese companies on the list, including Hong Kong-listed Sino Biopharm Limited (HK.01177) at No. 40 and affiliates Sinovac Life Sciences, whose parent company of Nasdaq-listed Sinovac Biotech Ltd. was ranked 17th.

Since the list is based on the 2021 sales revenue of prescription drug ranking of each pharmaceutical company, for some non-listed companies and companies that do not disclose specific product sales, part of the forecast is based on previous years' sales, in addition, the Japanese pharmaceutical companies' annual reports are from April 2021 to the end of March 2022, the list is split to calculate the 2021 annual report.

This time, Sino Biopharm was ranked 40th on the list. According to Sino Biopharm's 2021 annual report results, during the reporting period, the Group's revenue reached another record high of RMB 26.86 billion, up 13.6% year-on-year, and profit attributable to holders of the parent company was RMB 14.61 billion, up 427.2% year-on-year. Adherence to high-quality innovation has become an important source of motivation for Sino Biopharm's strong growth. In 2021, the three innovative drugs, Anlotinib Hydrochloride Capsules (Forcovir), Magnesium Isoglycyrrhizinate Injection (Tianqing Ganmei) and Penpulimab Injection, contributed a combined $6.4 billion, accounting for 24% of total revenue.

By the end of 2021, Sino Biopharm's products with more than 100 million sales amount reached 50, including six products of more than 1 billion yuan, eight products of 500 million to 1 billion, products with incremental sales of more than 100 million yuan and the growth rate of more than 50% are 11.

At the same time, Sino Biopharm is actively promoting the cooperation and expansion of drug development in the international scope. Currently, over 50 innovative drugs are in different clinical stages, and 10 innovative drugs are expected to be approved and marketed in the next three years, mainly focusing on anti-tumor, liver disease, respiratory and other fields. These include key products such as Factor VIII, Ebestine alpha injection and PD-L1.

Top 50 Global Pharmaceutical Companies in 2022 (USD billion)